Alphaherpesvirus vaccination, recombination and latency; a study in the natural host

α疱疹病毒疫苗接种、重组和潜伏期；

• 批准号: FT140101287
• 负责人: Prof Joanne Devlin
• 金额: $ 53.25万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-06-30 至 2019-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT140101287
• 关键词: Alphaherpesvirus; vaccination; recombination; latency; study

Attenuated alphaherpesvirus vaccines are used widely in production and companion animals to help control disease. These vaccines help to prevent clinical signs of disease following challenge with virulent viruses. There is also the potential to use these vaccines to help prevent latent herpesvirus infections, and to limit the opportunities for herpesvirus recombination to occur. This would enhance the ability to control disease in animal populations. This project aims to systematically study how vaccines may be used to limit latency and recombination events by studying avian infectious laryngotracheitis virus in the natural host leading to new insights into how vaccines may be used more efficaciously.

减毒α疱疹病毒疫苗广泛用于生产和伴侣动物，以帮助控制疾病。这些疫苗有助于预防强毒病毒攻击后的疾病临床体征。也有可能使用这些疫苗来帮助预防潜伏性疱疹病毒感染，并限制疱疹病毒重组发生的机会。这将提高控制动物种群疾病的能力。该项目旨在通过研究自然宿主中的禽传染性喉气管炎病毒，系统地研究如何使用疫苗来限制潜伏期和重组事件，从而对如何更有效地使用疫苗产生新的见解。